Today Juno Therapeutics Inc Had High Bullish Options Activity

 Today Juno Therapeutics Inc Had High Bullish Options Activity

In today’s session Juno Therapeutics Inc (JUNO) registered an unusually high (143) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious JUNO increase. With 143 contracts traded and 11684 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: JUNO161118C00035000 closed last at: $0.45 or 40% down. About 150,748 shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 31.40% since March 11, 2016 and is downtrending. It has underperformed by 36.86% the S&P500.

Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on November, 8. They expect $-0.64 earnings per share, down 18.52% or $0.10 from last year’s $-0.54 per share. After $-0.65 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts -1.54% EPS growth.

Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage

Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. $73 is the highest target while $39 is the lowest. The $51.80 average target is 85.33% above today’s ($27.95) stock price. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. As per Wednesday, November 18, the company rating was initiated by Goldman Sachs. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Buy” rating given on Monday, August 24 by Standpoint Research. FBR Capital maintained the shares of JUNO in a report on Friday, July 8 with “Outperform” rating. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Equal-Weight” rating by Barclays Capital on Wednesday, July 6. Standpoint Research downgraded the shares of JUNO in a report on Thursday, October 29 to “Hold” rating. The firm earned “Neutral” rating on Friday, July 8 by JP Morgan. The stock has “Buy” rating given by Standpoint Research on Tuesday, December 15. The rating was initiated by Citigroup with “Buy” on Thursday, February 25. Maxim Group maintained Juno Therapeutics Inc (NASDAQ:JUNO) on Friday, August 5 with “Buy” rating. As per Friday, January 29, the company rating was initiated by Suntrust Robinson.

According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”

Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.26, from 1.08 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Goldman Sachs Incorporated has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Morgan Stanley accumulated 1.15M shares or 0.02% of the stock. Shell Asset Management accumulated 0.01% or 11,697 shares. Raymond James And Assocs reported 5,839 shares or 0% of all its holdings. Vident Investment Advisory Ltd Limited Liability Company holds 0.09% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 15,776 shares. Aqr Management Ltd Limited Liability Company last reported 232,432 shares in the company. Guggenheim Capital Lc holds 0.01% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 115,404 shares. Mutual Of America Cap Mngmt Ltd Liability Company holds 1,370 shares or 0% of its portfolio. Macquarie Gp Ltd has invested 0.01% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Ubs Asset Management Americas holds 0% or 35,464 shares in its portfolio. Moreover, Omers Administration has 0.04% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 48,500 shares. Credit Suisse Ag, a Switzerland-based fund reported 123,916 shares. Perceptive Advisors Llc holds 0% or 1,113 shares in its portfolio. Royal State Bank Of Canada accumulated 0% or 5,942 shares. Winfield reported 20 shares or 0% of all its holdings.

Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $2.99 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

JUNO Company Profile

Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

Another recent and important Juno Therapeutics Inc (NASDAQ:JUNO) news was published by Fool.com which published an article titled: “Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data” on September 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment